INVERSAGO-PHARMA
7.9.2021 14:02:05 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound.
As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among others.
“Having demonstrated pharmacological characteristics that exceeded our expectations during IND-enabling preclinical studies, we’re excited to launch a second peripherally-acting CB1 blocker into the clinic with INV-202,” said Dr. Glenn Crater, MD, Chief Medical Officer of Inversago Pharma.
“With two unique, next generation CB1 blockers having entered the clinic in less than a year, we are rapidly bolstering our knowledge of this new class of drugs, which we believe may provide new treatment options for patients affected by a range of metabolic conditions,” said François Ravenelle, PhD, Chief Executive Officer of Inversago.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions. It is specifically designed to preferentially interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as PWS, NASH, T1D and diabetic nephropathy. For more information, visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UNPACK ’27: HOTELS.COM AFSLØRER DE REJSETRENDS, DER KOMMER TIL AT PRÆGE 202714.10.2026 09:00:00 CEST | Pressemeddelelse
Ny rapport fra Hotels.com identificerer fem rejsetrends, der vil komme til at præge 2027 lige fra efterspørgslen på små svipture og en genopblomstring af gotiske destinationer til næste års prognose for set-jetting. Hotels.com har i dag offentliggjort den årlige rapport Unpack ’27: The Trends in Travel™, der undersøger de destinationer, oplevelser og adfærdsmønstre, der forventes at præge rejsebranchen i 2027. Baseret på indsigter fra Hotels.com samt global rejseresearch og social listening afslører Unpack ‘27 de nye steder, der tiltrækker rejsende i 2027, og nogle overraskende ting, de foretager sig, når de først er ankommet. “At rejse handler om at skabe minder, og Unpack ‘27 afslører de destinationer og oplevelser, der præger netop de øjeblikke”, siger Ariane Gorin, CEO for Expedia Group. “I 2027 vil rejsende være mere bevidste i valget af deres næste eventyr og søge oplevelser, der er mere personlige og meningsfulde for dem. Vi gør det nemmere at opdage, planlægge og booke den rigt
Otometrics Launches Aurical® IQ – Delivering the First and Only Guided Workflow Enabling up to 51% Faster Fittings and 39% Improved Workflow Accuracy14.10.2026 09:00:00 CEST | Press release
Clinical evaluations demonstrated up to 51% faster fitting times for experienced clinicians and 39% improved workflow accuracy for newer clinicians; Aurical IQ also supports the NAL-NL3 Fitting System Otometrics, the Hearing & Balance division of Natus Sensory, today announced Aurical® IQ, the next generation of its trusted hearing aid fitting and verification platform. Combining the first and only Guided Workflow for hearing aid fitting and verification, support for the NAL-NL3 Fitting System and a redesigned Otosuite® software experience, Aurical IQ is designed to help hearing care professionals work more efficiently and follow best-practice fitting procedures with greater consistency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014023398/en/ Aurical IQ Guided Workflow provides structured, step-by-step guidance through the fitting and verification process, designed to make best-practice fitting easier to follow. A ne
NEURA Robotics Introduces Neuron AI: The Brain of the Physical World14.10.2026 08:29:00 CEST | Press release
Beyond vision: Neuron AI brings 3D vision, touch, audio, robot state and language together with memory in one Perception-Language-Action (PLA) model, so robots can react to what they cannot seeOne model, every body: Trained on real-world robot data, simulation-amplified data and human demonstrations, Neuron AI runs across five NEURA robot embodiments and their grippers and handsFrom skill to fleet: Customers fine-tune Neuron AI for their own tasks and deploy skills across robot fleets via the platform Neuraverse, with Time-to-Skill as the central measure of progressAI built in Germany: Developed and trained in-house in Metzingen, GermanyLive at NVIDIA GTC Berlin: NEURA’s humanoid 4NE1 will complete an eleven-minute laundry task, fully autonomous from start to finish NEURA Robotics (“NEURA”) today introduced Neuron AI, its multimodal foundation model for Physical AI. Combining 3D vision, touch, audio, robot state and language with memory, Neuron AI enables robots to act on information b
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering14.10.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Acquisition brings together two highly complementary, science-backed skincare brands ZO Skin Health’s premium daily multi-step regimens complement Alastin’s regenerative skincare portfolio primarily focused on peri-procedure support Transaction expands Galderma’s Dermatological Skincare portfolio and offering in the attractive, fast-growing physician-dispensed skincare segment1 Galderma’s unique Integrated Dermatology Strategy, global scale and omni-channel execution capabilities expected to support ZO Skin Health’s next phase of growth Acquisition of 100% of ZO Skin Health for an enterprise value of 1.5 billion USD, expected to be Core EPS neutral in the first full year following closing Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone
Pretium Expands Middle East Presence with Abu Dhabi Office14.10.2026 06:02:00 CEST | Press release
Office will enable Pretium to engage more directly with institutional partners across the Middle East Pretium, a specialized investment firm with approximately $70 billion in assets under management1, today announced the opening of an office in Abu Dhabi. The office will operate within Abu Dhabi Global Market (“ADGM”), the international financial center of Abu Dhabi, providing proximity to some of the world’s leading institutional investors. The Abu Dhabi office marks an important step in the continued evolution of Pretium’s business. From its roots in U.S. residential real estate, Pretium has built a scaled investment platform spanning real estate equity and credit. A dedicated presence in Abu Dhabi will enhance the Firm’s connections to clients in the region as it continues to develop new investment solutions. “Abu Dhabi is home to some of the world’s most sophisticated and forward-looking institutional investors,” said Don Mullen, Founder and CEO of Pretium. “An on-the-ground presen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom